Vol 8, Supplement 6 (December 20, 2019): Translational Cancer Research

Editorial Commentary

Discernable differences in the genetic and molecular profile of cerebellar glioblastoma

Muhibullah S. Tora, D. Cory Adamson

PDF Pages: S553-S558 Full Text (1080) COI Form Open Access

High predictability for identifying Lynch syndrome via microsatellite instability testing or immunohistochemistry in all Lynch-associated tumor types

John M. Carethers

PDF Pages: S559-S563 Full Text (2487) COI Form Open Access

Targeting the reversible drug-tolerant state: aurora kinase A, is that the final answer?

Kenichi Suda

PDF Pages: S564-S568 Full Text (1872) COI Form Open Access

Revisiting anti-angiogenic therapy for recurrent glioblastoma

Katherine B. Peters

PDF Pages: S569-S572 Full Text (1579) COI Form Open Access

Robotic surgery in early-stage endometrial cancer

Giacomo Corrado, Simone Bruni, Enrico Vizza

PDF Pages: S573-S576 Full Text (2327) COI Form Open Access

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma

Dana Mitchell, Mahua Dey

PDF Pages: S577-S579 Full Text (1615) COI Form Open Access

Pseudoprogression in low-grade glioma

Jason M. Slater, Helen A. Shih

PDF Pages: S580-S584 Full Text (1320) Open Access

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma

Yue Zhang, Shenhong Wu

PDF Pages: S585-S588 Full Text (1577) COI Form Open Access

Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial

Ivo W. Tremont-Lukats, Bin S. Teh

PDF Pages: S589-S591 Full Text (3825) COI Form Open Access

Local therapy in patients with metastatic prostate cancer: a new standard of care?

Benjamin Harper, Zachary Klaassen, Christopher J. D. Wallis

PDF Pages: S592-S594 Full Text (1766) COI Form Open Access

Androgen receptor splice variant 7 in castration resistant prostate cancer treated with hormonal therapy: what is in the pipeline?

Martina Chirra, Roberto Petrioli, Giandomenico Roviello

PDF Pages: S595-S597 Full Text (1011) COI Form Open Access

Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial

Alessandro Russo, Katherine A. Scilla, Christian Rolfo

PDF Pages: S598-S602 Full Text (1899) Open Access

Stepping in the right direction but still some ways to go

Alfredo Addeo, Giuseppe Luigi Banna, Alex Friedlaender

PDF Pages: S603-S605 Full Text (749) COI Form Open Access

New approaches to model glioblastoma in vitro using brain organoids: implications for precision oncology

Guillermo A. Gomez, Mariana Oksdath, Michael P. Brown, Lisa M. Ebert

PDF Pages: S606-S611 Full Text (2614) COI Form Open Access

Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study

Sara Elena Rebuzzi, Francesco Facchinetti, Marcello Tiseo

PDF Pages: S612-S617 Full Text (2345) Open Access

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?

Alfonso Fiorelli, Fabiana Vitiello, Floriana Morgillo, Mario Santagata, Chiara Spuntarelli, Marina Di Domenico, Mario Santini, Andrea Bianco

PDF Pages: S618-S620 Full Text (3904) COI Form Open Access

A mechanism for the tissue specificity in BAP1 cancer syndrome

Yuichi J. Machida

PDF Pages: S621-S624 Full Text (1578) COI Form Open Access

Immune checkpoint inhibitors and the shared epitope theory: from hypothesis to practice

Shalom Lerrer, Adam Mor

PDF Pages: S625-S627 Full Text (1240) COI Form Open Access

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer

Yosuke Miura, Norimitsu Kasahara, Noriaki Sunaga

PDF Pages: S628-S632 Full Text (1673) COI Form Open Access

Neoadjuvant therapy in localized non-small cell lung cancer: can we do better than chemotherapy?

Brittney Chau, Ashwin Shinde, Arya Amini

PDF Pages: S633-S635 Full Text (1234) COI Form Open Access

Conditional reprogramming technology: a new tool for personalized medicine in bladder cancer?

Hiroshi Miyamoto

PDF Pages: S636-S638 Full Text (1434) COI Form Open Access

N-Myc-mediated epigenetic reprogramming in advanced prostate cancer: personalized medicine and quality of biological samples

Saverio Bettuzzi

PDF Pages: S639-S641 Full Text (693) Open Access

Letter to the Editor

“Primary” and “secondary” muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes

Eugene J. Pietzak, Hikmat Al-Ahmadie, Aleksandra Walasek, Dean F. Bajorin, Jonathan E. Rosenberg, Bernard H. Bochner, David B. Solit, Gopa Iyer

PDF Pages: S642-S644 Full Text (1332) Open Access

News

Application of the CARE guideline as reporting standard in the Translational Cancer Research

Editorial Office

PDF Pages: S645 Full Text (1017) Open Access

Disclosure:

This supplement was published without any sponsorship or funding.